Skip to main content
SpringerLink
Log in

A warning regarding use in patients with Barrett's esophagus has been added to product information for risedronic acid in the EU.

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Heads of Medicines Agencies.Risedronate and the risk of oesophageal cancer Internet Document: [1 page], 14 Sep 2012. Available from: URL: http://www.hma.eu/

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A warning regarding use in patients with Barrett's esophagus has been added to product information for risedronic acid in the EU.. React. Wkly. 1420, 3 (2012). https://doi.org/10.2165/00128415-201214200-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214200-00007

Keywords

Search

Navigation